Presurgical trial of metformin in overweight and obese patients with newly diagnosed breast cancer

Kevin Kalinsky; Katherine D. Crew; Susan Refice; Tong Xiao; Antai Wang; Sheldon M. Feldman; Bret Taback; Aqeel Ahmad; Serge Cremers; Hanina Hibshoosh; Matthew Maurer; Dawn L. Hershman

doi:10.3109/07357907.2014.889706

Presurgical trial of metformin in overweight and obese patients with newly diagnosed breast cancer

Kevin Kalinsky, Katherine D. Crew, Susan Refice, Tong Xiao, Antai Wang, Sheldon M. Feldman, Bret Taback, Aqeel Ahmad, Serge Cremers, Hanina Hibshoosh, Matthew Maurer, Dawn L. Hershman

Research output: Contribution to journal › Article › peer-review

68 Scopus citations

Abstract

Introduction: We conducted a presurgical trial to assess the tissue-related effects of metformin in overweight/obese breast cancer (BC) patients. Methods: Metformin 1,500 mg daily was administered to 35 nondiabetics with stage 0-III BC, body mass index (BMI) ≥ 25 kg/m². The primary endpoint was tumor proliferation change (i.e., ki-67). Tumor proliferation change was compared to untreated historical controls, matched by age, BMI, and stage. Results: There was no reduction in ln(ki-67) after metformin (p = .98) or compared to controls (p = .47). There was a significant reduction in BMI, cholesterol, and leptin. Conclusion: Despite no proliferation changes, we observed reductions in other relevant biomarkers.

Original language	English (US)
Pages (from-to)	150-157
Number of pages	8
Journal	Cancer Investigation
Volume	32
Issue number	4
DOIs	https://doi.org/10.3109/07357907.2014.889706
State	Published - Apr 2014
Externally published	Yes

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

Keywords

Breast cancer
Hispanic
Insulin resistance
Ki-67
Metformin
Presurgical

Access to Document

10.3109/07357907.2014.889706

Cite this

@article{30e52b53f4e14e9c88c0664d72fbb4da,

title = "Presurgical trial of metformin in overweight and obese patients with newly diagnosed breast cancer",

abstract = "Introduction: We conducted a presurgical trial to assess the tissue-related effects of metformin in overweight/obese breast cancer (BC) patients. Methods: Metformin 1,500 mg daily was administered to 35 nondiabetics with stage 0-III BC, body mass index (BMI) ≥ 25 kg/m2. The primary endpoint was tumor proliferation change (i.e., ki-67). Tumor proliferation change was compared to untreated historical controls, matched by age, BMI, and stage. Results: There was no reduction in ln(ki-67) after metformin (p = .98) or compared to controls (p = .47). There was a significant reduction in BMI, cholesterol, and leptin. Conclusion: Despite no proliferation changes, we observed reductions in other relevant biomarkers.",

keywords = "Breast cancer, Hispanic, Insulin resistance, Ki-67, Metformin, Presurgical",

author = "Kevin Kalinsky and Crew, {Katherine D.} and Susan Refice and Tong Xiao and Antai Wang and Feldman, {Sheldon M.} and Bret Taback and Aqeel Ahmad and Serge Cremers and Hanina Hibshoosh and Matthew Maurer and Hershman, {Dawn L.}",

note = "Funding Information: Financial Support: This research was funded by the Breast Cancer Research Foundation and New York Obesity Research Council. This publication was also supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant Number KL2 TR000081. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.",

year = "2014",

month = apr,

doi = "10.3109/07357907.2014.889706",

language = "English (US)",

volume = "32",

pages = "150--157",

journal = "Cancer Investigation",

issn = "0735-7907",

publisher = "Informa Healthcare",

number = "4",

}

TY - JOUR

T1 - Presurgical trial of metformin in overweight and obese patients with newly diagnosed breast cancer

AU - Kalinsky, Kevin

AU - Crew, Katherine D.

AU - Refice, Susan

AU - Xiao, Tong

AU - Wang, Antai

AU - Feldman, Sheldon M.

AU - Taback, Bret

AU - Ahmad, Aqeel

AU - Cremers, Serge

AU - Hibshoosh, Hanina

AU - Maurer, Matthew

AU - Hershman, Dawn L.

N1 - Funding Information: Financial Support: This research was funded by the Breast Cancer Research Foundation and New York Obesity Research Council. This publication was also supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant Number KL2 TR000081. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

PY - 2014/4

Y1 - 2014/4

N2 - Introduction: We conducted a presurgical trial to assess the tissue-related effects of metformin in overweight/obese breast cancer (BC) patients. Methods: Metformin 1,500 mg daily was administered to 35 nondiabetics with stage 0-III BC, body mass index (BMI) ≥ 25 kg/m2. The primary endpoint was tumor proliferation change (i.e., ki-67). Tumor proliferation change was compared to untreated historical controls, matched by age, BMI, and stage. Results: There was no reduction in ln(ki-67) after metformin (p = .98) or compared to controls (p = .47). There was a significant reduction in BMI, cholesterol, and leptin. Conclusion: Despite no proliferation changes, we observed reductions in other relevant biomarkers.

AB - Introduction: We conducted a presurgical trial to assess the tissue-related effects of metformin in overweight/obese breast cancer (BC) patients. Methods: Metformin 1,500 mg daily was administered to 35 nondiabetics with stage 0-III BC, body mass index (BMI) ≥ 25 kg/m2. The primary endpoint was tumor proliferation change (i.e., ki-67). Tumor proliferation change was compared to untreated historical controls, matched by age, BMI, and stage. Results: There was no reduction in ln(ki-67) after metformin (p = .98) or compared to controls (p = .47). There was a significant reduction in BMI, cholesterol, and leptin. Conclusion: Despite no proliferation changes, we observed reductions in other relevant biomarkers.

KW - Breast cancer

KW - Hispanic

KW - Insulin resistance

KW - Ki-67

KW - Metformin

KW - Presurgical

UR - http://www.scopus.com/inward/record.url?scp=84898740537&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898740537&partnerID=8YFLogxK

U2 - 10.3109/07357907.2014.889706

DO - 10.3109/07357907.2014.889706

M3 - Article

C2 - 24605899

AN - SCOPUS:84898740537

SN - 0735-7907

VL - 32

SP - 150

EP - 157

JO - Cancer Investigation

JF - Cancer Investigation

IS - 4

ER -

Presurgical trial of metformin in overweight and obese patients with newly diagnosed breast cancer

Abstract

All Science Journal Classification (ASJC) codes

Keywords

Access to Document

Other files and links

Fingerprint

Cite this